ClinicalTrials.gg
RecruitingNCT07426003HENUpdated Aug 6, 2026

Healthy Volunteers Enteral Nutrition Study (HEN)

An interventional study of Kate Farms Peptide 1.5 and Crohn's disease exclusion diet in Enteral Nutrition's Effect on the Gut, sponsored by James Lewis. Recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by James Lewis · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This research study is being conducted to determine the effects of enteral nutrition on healthy people. Enteral nutrition for the purpose of this study refers to the use of a specially developed formula taken by mouth that provides all essential nutrition either in the absence of food or to supplement the intake of foods. Enteral nutrition can be used for many reasons, such as to gain or lose weight, to treat food allergies, or to reduce inflammation in certain intestinal diseases. We would like to understand the effects of enteral nutrition in the absence of intestinal inflammation.

Read the detailed description

Crohn's disease is an immune mediated condition that can affect any area of the gastrointestinal tract. The etiology is still unclear but is thought to be an aberrant response to the gut microbiota, inducing intestinal and systemic inflammation. Given the role of the immune system in the pathogenesis of Crohn's disease, the cornerstone of therapy has been targeted immunosuppression. However, despite the advances in pharmacologic treatments that have been seen in the past 20 years, a significant number of patients either do not respond to therapy or lose response after experiencing a benefit. In addition, immunosuppression is associated with unwanted adverse effects. As such, there is a need to develop therapeutic approaches that address the underlying stimuli that leads to the inflammation of Crohn's disease.

This is an outpatient randomized controlled trial of 20 healthy volunteers who will be assigned to either Partial Enteral Nutrition (PEN) defined as 60% of calories from Kate Farms Peptide 1.5 formula and 40% of calories from the Crohn's Disease Exclusion Diet (CDED) (N=10) vs. Exclusive Enteral Nutrition (EEN) defined as 100% of calories from Kate Farms Peptide 1.5 formula (N=10) for 3 days. The purpose of the study is to understand the changes in colon transit time and the microbiome and metabolome that result from consumption of the assigned diet. Blood and urine will be collected at screening and for 3 of 4 days that the participants are under study observation. Stool will be collected on all 4 days if the participant has a bowel movement on each day. Participants will also be given sitz markers on day one of the study and will undergo one or two x-rays. Diet surveys will also be collected during the 4 days of observation.

Considering the link between gut microbiome and development of inflammatory bowel diseases, there has been a growing interest in dietary modifications aiming to treat or even prevent the development of disease. Dietary therapies are a potential therapeutic alternative in Crohn's disease. Exclusive enteral nutrition (EEN), the provision of 90% to 100% of daily caloric intake with a meal replacement formula, is as efficacious as corticosteroids in pediatric Crohn's disease and is promoted as a first-line treatment over corticosteroids. However, it is used less in adults as it is not well tolerated and leads to poor adherence. Partial enteral nutrition (PEN), the provision of approximately 50-80% of calories from a meal replacement formula, has emerged as a potential, better tolerated strategy to treat CD. Studies have shown that PEN may help to treat Crohn's disease even though it may not be as efficacious as EEN. The mechanisms by which enteral nutrition may be useful in the treatment of CD are unknown but some evidence points to immunomodulation of the gastrointestinal tract, promoting mucosal healing through changes in cytokine profiles, inducing microbiome changes and decreasing the exposure to food and additives that can reduce the epithelial barrier function.

CDED is characterized by mandatory and optional foods. The mandatory foods are chicken breast, eggs, potatoes, apples and bananas. The optional foods are predominantly a range of fruits and vegetables and non-gluten containing grains. Because EEN and PEN with CDED appear to be comparably efficacious, it suggests that the food which is being excluded is more important than the quantity of formula consumed. This is further evidenced by the observation that the choice of enteral formula does not appear to impact the efficacy of EEN.6

The main barrier to use of EEN or CDED is the restrictive nature of the diet. The investigators hypothesize that better characterization of the biologic effects of EEN and PEN with CDED would allow for development of more liberalized diets that achieve comparable efficacy. The investigators propose to leverage modern omics technologies to characterize the microbiome and metabolome of EEN and PEN with CDED among healthy volunteers to aid in the development of rational and perhaps personalized diets for patients with Crohn's disease. The investigators have elected to conduct this research among healthy volunteers rather than in patients with Crohn's disease so as to avoid the confounding effect of intestinal inflammation.

02

Conditions studied

  • Enteral Nutrition's Effect on the Gut

Keywords

  • enteral nutrition
  • healthy volunteers
03

In context

Lead sponsor

James Lewis is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be able to read and understand English
  2. Must be able to sign a consent form for the study

Exclusion criteria

Exclusion Criteria:

  1. \<20 or >30
  2. Unintentional weight loss of >10% in the last 3-6 months
  3. Kidney disease
  4. Diagnosis of cirrhosis
  5. Taking diuretics
  6. Anemia - \<lower limit of normal in men or \<10 g/dL in women.
  7. Taking iron supplements within 2 weeks for Visit 2.1
  8. Taking prebiotic or probiotic supplements or any supplement including a multivitamin within 2 weeks of Visit 2.1
  9. Taking antibiotics less than 4 weeks prior to Visit 2.1
  10. Diarrhea in the 2 weeks prior to Visit 2.1
  11. Diabetes mellitus
  12. Diagnosis of congestive heart failure
  13. Diagnosis of inflammatory bowel disease or celiac disease
  14. Bowel resection other than an appendectomy
  15. Pregnancy or breastfeeding
  16. Intolerance or allergy to nutritional formula, chicken, eggs, apples, banana, potatoes
  17. Using protein supplements, including powder added to food or drinks within 2 weeks of Visit 2.1
  18. Baseline bowel frequency less than every 2 days or greater than 3 times daily
  19. Student or employee of any one of the investigators.
  20. Anyone who cannot receive study payment (e.g. visa constraints).
  21. Any condition that the investigator feels may limit the volunteer's ability to complete the study protocol.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Active comparator
    Partial Enteral Nutrition and the Crohn's Disease Exclusion Diet

    Participants will drink Kate Farms Peptide 1.5 for 60% of their calories and follow the Crohn's Disease Exclusion Diet for the remainder of their calories

    Dietary Supplement: Kate Farms Peptide 1.5 · Other: Crohn's disease exclusion diet

  • Active comparator
    Exclusive enteral nutrition

    Participants will consume Kate Farms Peptide 1.5 exclusively except water, and coffee and tea with no sweetner or cream/milk for 3 days

    Dietary Supplement: Kate Farms Peptide 1.5

Interventions

  • Dietary supplementKate Farms Peptide 1.5

    Kate Farms Peptide 1.5

  • OtherCrohn's disease exclusion diet

    This study will use the components of the Crohn's disease exclusion diet Phase 1 which includes chicken breast, eggs, potatoes, bananas and apples

06

What researchers measure

Primary outcomes

  1. number of sitz markers at 72 hours

    Number of sitz markers that are present in an abdominal x-ray 72 hours after the participant takes the sitz mark capsule

    Time frame: 72 hours after taking the sitzmark capsule

07

Study locations

1 of 1 sites recruiting
  • Penn Center for Advance Medicine, University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Due to the small sample size, there is risk of participant identification. However, we will consider requests to access deidentified data on an individual basis and under a data use agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Apr 2027, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2026
First posted
Feb 23, 2026
StartActual
Jun 17, 2026
Primary completionEst.
Apr 2027
CompletionEst.
May 2027
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07426003
Lead sponsor
James Lewis
Responsible party
James Lewis (Professor of Medicine and Epidemiology, University of Pennsylvania) — Sponsor-investigator
First posted
Feb 23, 2026
Start date
Jun 17, 2026
Primary completion
Apr 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Aug 6, 2026

Study contacts

Raksha Shastry, MPH
Contact
Raksha.Shastry@PennMedicine.upenn.edu
267-896-3160
HEN Study General Email
Contact
HenStudy@pennmedicine.upenn.edu
James Lewis, MD, MSCE
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion